Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rituximab by Biogen for Hairy Cell Leukemia: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Hairy Cell Leukemia. According to GlobalData, Phase...
Rituximab by F. Hoffmann-La Roche for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma....
Rituximab by F. Hoffmann-La Roche for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma...
Rituximab by F. Hoffmann-La Roche for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma....
Rituximab by Biogen for Neuromyelitis Optica (Devic's Syndrome): Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase III for Neuromyelitis Optica (Devic's Syndrome). According to GlobalData,...
Rituximab by Biogen for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase...
Rituximab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma. According...
Rituximab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma. According...
Rituximab by Biogen for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase...
Rituximab by Biogen for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...